Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions

Monoclonal antibodies (mAbs) have become attractive tools for both the treatment and prevention of influenza A viruses due to their ability to target several viral components, which confers broad therapeutic potential. Advances in biotechnology, such as hybridoma technology, phage display technology...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Nahed N. Mahrous, Ohoud S. Alhumaidan, Abdulaziz S. Alkhoshaiban, Rawan T. Tafish, Fatimah F. Al-Ghnnam, Maha Althubyani, Abeer Al-Hubaysh, Yahya F. Jamous
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-01-01
Serie:	Frontiers in Microbiology
Soggetti:	antiviral therapy broadly neutralizing antibodies (bnAbs) influenza A virus mAb resistant monoclonal antibodies (mAbs)
Accesso online:	https://www.frontiersin.org/articles/10.3389/fmicb.2025.1738181/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!